News
Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer
SAN DIEGO, Calif., March 17, 2021 – Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create...
Ambrx Appoints Audit Executive Chris Nolet to Board of Directors
SAN DIEGO, Calif., February 23, 2021 – Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create...
FDA Grants ARX788 Fast Track Designation for HER2-positive Metastatic Breast Cancer
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Ambrx announced that the U.S. Food and Drug Administration (FDA) granted ARX788 Fast...